If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Taltz ® (ixekizumab) injection
80 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Taltz® (Ixekizumab): Dosing for Plaque Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
PsO: 160 mg at week 0, 80 mg weeks 2,4,6,8,12, then 80 mg every 4 weeks. PsA: 160 mg at week 0, then 80 mg every 4 weeks. AS/r-axSpA: 160 mg at week 0, then 80 mg every 4 weeks. nr-axSpA: 80 mg every 4 weeks.
Plaque Psoriasis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80-mg injections) at week 0
-
80 mg at weeks 2, 4, 6, 8, 10, and 12, then
-
80 mg Q4W.1
Psoriatic Arthritis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80-mg injections) at week 0, then
-
80 mg Q4W.1
For PsA patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.1
Ixekizumab may be administered alone or in combination with a cDMARD (e.g., MTX).1
Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80 mg injections) at week 0, then
-
80 mg Q4W.1
Non-radiographic Axial Spondyloarthritis
Ixekizumab is administered by SC injection. The recommended dose is 80 mg every 4 weeks.1
Ixekizumab General Administration Guidelines
Tuberculosis Assessment Prior to Initiation of Ixekizumab
Evaluate patients for TB infection prior to initiating treatment with ixekizumab.1
Important Administration Instructions
There are 2 presentations for ixekizumab (ie, autoinjector and prefilled syringe). The ixekizumab “Instructions for Use” for each presentation contains more detailed instructions on the preparation and administration of ixekizumab.
Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in SC injection technique using the autoinjector or prefilled syringe.
Each injection is to be administered
-
at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and
-
not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.
Administration of ixekizumab in the upper, outer arm may be performed by a caregiver or healthcare provider.
If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.1
Enclosed Prescribing Information
TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
cDMARD = conventional disease-modifying antirheumatic drug
MTX = methotrexate
NSAID = nonsteroidal anti-inflammatory drug
PsA = psoriatic arthritis
Q4W = every 4 weeks
SC = subcutaneous
TB = tuberculosis
TNF = tumor necrosis factor
Date of Last Review: June 17, 2020